Perioperative chemotherapy with modified FOLFIRINOX for nonmetastatic pancreatic cancer: a new standard of care?

Future Oncol. 2021 Jan;17(3):229-233. doi: 10.2217/fon-2020-0836. Epub 2020 Dec 11.

Authors

Imad Radi¹, Ramy Samaha¹, Joanna El Hajj¹, Hady Samaha¹, Hampig Raphael Kourie¹

Affiliation

¹ Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, 166830, Lebanon.

PMID: 33305614
DOI: 10.2217/fon-2020-0836

No abstract available

Keywords: borderline resectable; locally advanced; modified FOLFIRINOX; pancreatic cancer; pancreatic surgery; perioperative chemotherapy.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biomarkers, Tumor / genetics
Biomarkers, Tumor / metabolism
Chemotherapy, Adjuvant
Humans
Pancreatic Neoplasms / diagnosis
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / pathology
Pancreatic Neoplasms / surgery
Perioperative Period
Standard of Care
Treatment Outcome

Substances

Antineoplastic Agents
Biomarkers, Tumor